Further, protein groups differentially expressed in response to HIV-Tat treatment at multiple time points may represent potentially important molecular switches and are good targets for follow up validation work in the identification of molecular biomarkers for the characterization or treatment of HAND. The gene discussed is TAT; the disease is HIV-associated neurocognitive disorder.